Table 1 Vaccine effectiveness against RVGE hospitalization during the post-vaccine period by age group
Age Group | Direct VE, % (95% CI) | Indirect VE, % (95% CI) | Overall VE, % (95% CI) | Total VE, % (95% CI) |
|---|---|---|---|---|
< 1 | 80* (70, 87) | 79* (66, 87) | 88* (82, 92) | 96* (93, 97) |
1 | 92* (87, 95) | 59* (33, 76) | 79* (65, 88) | 97* (95, 98) |
2 | 87* (76, 93) | 43* (4, 67) | 68* (44, 83) | 93* (86, 96) |
3 | 96* (89, 99) | 42 (− 2, 68) | 71* (47, 84) | 97* (93, 99) |
4 | 81* (53, 93) | 36 (− 25, 68) | 59* (22, 79) | 88* (70, 96) |
0–4 | 87* (83, 90) | 60* (48, 69) | 78* (71, 83) | 95* (93, 96) |
5–9 | 47 (− 12, 79) | 48* (30, 61) | 50* (34, 63) | 72* (42, 89) |
10–14 | 46* (14, 67) | Equivalent to indirect VEa | ||
15–24 | 42* (10, 62) | |||
25–44 | 56* (36, 70) | |||
45–64 | 35* (9, 53) | |||
All ages | 69* (62, 76) |